Improved outcome for acute lymphoblastic leukemia in children of a developing country: Results of the Chilean National Trial PINDA 87

Medical and Pediatric Oncology

Volumn 33, Issue 2, 1999, Pages 88-94

  Campbell, Myriam ^a,j   Salgado, C ^b   Quintana, J ^c   Becker, A ^d   Vargas, L ^e   Cabrera, M E ^f   Beresi, V ^c   Rojas, J ^g   Paez, E ^j   Tapia, S ^h   Zolezzi, P ^j   Advis, P ⁱ  

^a HOSPITAL ROBERTO DEL RÍO   (Chile)

^b Pediatra Reumatólogo Unidad Inmuno Reumatología Hospital Dr Exequiel González Cortés   (Chile)

^c HOSPITAL LUIS CALVO MACKENNA   (Chile)

^d HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^e HOSPITAL SAN JUAN DE DIOS   (Chile)

^f HOSPITAL DEL SALVADOR   (Chile)

^g Hospital Regional de Concepcion Dr Guillermo Grant Benavente   (Chile)

^h Hospital Dr Gustavo Fricke   (Chile)

ⁱ HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^j NONE

more..

Author keywords

Cancer clinical trial; Childhood acute lymphoblastic leukemia; Cranial irradiation; Immunophenotype

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHILE; FEMALE; HUMAN; IMMUNOPHENOTYPING; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKULL IRRADIATION; SURVIVAL RATE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CHILE; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METHOTREXATE; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0032798602     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199908)33:2<88::AID-MPO5>3.0.CO;2-Z     Document Type: Article

References (19)

1. Salgado C, Fuentes Y, Weinstein F, et al. Experiencia de 878 pacientes oncológicos tratados por GOPECH. Pediatria 1998;31: 68.
2. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus 1990;33:439-459.
3. Vargas L, Quintana J, Campbell M, et al. Protocolo BFM-83 para tratamiento de leucemia linfoblástica aguda. Análisis de las primeras fases en 53 pacientes. Pediatria 1988;31:68.
4. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the Multicenter Trial ALL BFM 86. Blood 1994;84:3122-3133.
5. Benett JM, Catovski D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol 1976;33:451-458.
6. Greaves MS, Colman SM, Beard MEJ, et al. Geografical distribution of acute lymphoblastic leukaemia FAB type: Second report of the collaborative group study. Leukemia 1993;7:27-34.
7. Cabrera ME, Labra S, Ugarte S, et al. Inmunofenotipo, características clínicas y laboratorio de la leucemia linfoblástica aguda en Chile. Rev Med Chile 1996;124:293-299.
8. Langermann HJ, Henze G, Riehm H. Abschatzung der tumorzellmasse bei der akuten lymphoblastischen leukaemieim Kindersalter: Prognostische Bedeutung und praktische anwendung. Klin Padiatr 1982;194:209-214.
9. Riehm H, Reiter a, Schrappe M, et al. Die corticosteroidabhangige dezimierung der leukamiezellzahl im blut als prognosefaktor bei der akuten lymphoblastischen leukamie im Kindersalter (Therapiestudie ALL BFM 83). Klin Padiatr 1987;199:151-158.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977;35:1-39.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1986; 50:163-168.
13. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-193.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22: 719-748.
15. Chessells JM, Bailey C, Richards SM (for the Medical Research Council Working Party on Childhood Leukaemia). Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet 1995;345:143-148.
16. Vecchi V, Arco M, Basso G, et al. (for the Associazone Italiana Ematología Oncologia Pediatrica). Risk-directed therapy for childhood acute lymphoblastic leukemia. Cancer 1993;72:2517-2524.
17. Pui CH, Crist W. Biology and treatment of acute lymphoblastic leukemia. J Pediatr 1994;124:491-503.
18. Tubergen D, Gilchrist G, O'Brien R, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 1993;11:527-537.
19. Rivera G, Pinkel D, Simone J, et al. Treatment of acute lymphoblastic leukemia. N Eng J Med 1993;329:1289-1295.